Charles River Laboratories (CRL)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $16.19B
Last updated: Nov 17, 2026 at 11:05 AM ET
Charles River Laboratories (CRL) P/E Ratio & Valuation History
Charles River Laboratories (CRL) trades at 31.8x trailing earnings and 4.0x sales. Its P/E of 31.8x is above its 5-year median of 19.4x. Its forward P/E is 26.6x. The median P/E across 10 similar companies is 25.3x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 19.5% higher over the next year. Its free cash flow yield is 2.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 31.8x |
| Forward P/E | 26.6x |
| Price to sales | 4.0x |
| Price to book | 5.0x |
| EV/EBITDA | 63.0x |
| Price to FCF | 40.1x |
| EV/FCF | 45.7x |
| PEG | 0.1 |
| FCF yield | 2.5% |
Historical Medians
Against its 10-year medians, its P/E is 55.1% above 20.5x, its P/S is 48.1% above 2.7x and its P/B is 11.1% above 4.5x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 31.8x | 19.4x | 20.5x |
| P/S | 4.0x | 2.6x | 2.7x |
| P/B | 5.0x | 3.2x | 4.5x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 16.7x in 2016 to 36.5x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $199.48 | 19.4x | 2.5x | 3.1x |
| 2024 | $184.60 | 17.9x | 2.3x | 2.7x |
| 2023 | $236.40 | 22.2x | 2.9x | 3.4x |
| 2022 | $217.90 | 19.6x | 2.8x | 3.8x |
| 2021 | $376.78 | 36.5x | 5.4x | 7.7x |
| 2020 | $249.86 | 30.7x | 4.3x | 6.0x |
| 2019 | $152.76 | 22.7x | 2.9x | 4.7x |
| 2018 | $113.18 | 18.8x | 2.4x | 4.2x |
| 2017 | $109.45 | 20.7x | 2.8x | 5.0x |
| 2016 | $76.19 | 16.7x | 2.2x | 4.4x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CRL
What is CRL's forward P/E ratio?
Charles River Laboratories has a forward P/E ratio of 26.6x.
Is CRL stock overvalued?
GNG's valuation label for CRL is Overvalued. Its P/E of 31.8x compares with a median of 25.3x across 10 similar companies.
What is CRL's price to sales ratio?
Charles River Laboratories has a price to sales ratio of 4.0x.
What is Charles River Laboratories's average P/E ratio over 5 years?
Charles River Laboratories's median P/E over the last 5 years is 19.4x, from 60 month-end values through Oct 2026.
What is CRL's PEG ratio?
Charles River Laboratories has a PEG ratio of 0.1.
CRL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts